Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

• Published in: Journal of thoracic oncology Vol. 14; no. 5; pp. 867 - 875
• Main Authors: Wu, Yi-Long, Lu, Shun, Cheng, Ying, Zhou, Caicun, Wang, Jie, Mok, Tony, Zhang, Li, Tu, Hai-Yan, Wu, Lin, Feng, Jifeng, Zhang, Yiping, Luft, Alexander Valerievich, Zhou, Jianying, Ma, Zhiyong, Lu, You, Hu, Chengping, Shi, Yuankai, Baudelet, Christine, Cai, Junliang, Chang, Jianhua
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2019; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Chinese population; Nivolumab; NSCLC; Phase III clinical study; Chinese population; NSCLC; Nivolumab; Phase III clinical study

Data on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab in a predominantly Chinese patient population with previously treated NSCLC. CheckMate 078 was a randomized, open-label, phase III clinical trial in pati...